Expert Review of Anticancer Therapy

Papers
(The TQCC of Expert Review of Anticancer Therapy is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Triple-negative breast cancer: promising prognostic biomarkers currently in development76
TIM-3 pathway dysregulation and targeting in cancer52
Molecular therapeutic targets in non-small cell lung cancer43
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis37
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy30
The potential of PSMA-targeted alpha therapy in the management of prostate cancer30
Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies28
TKIs in combination with immunotherapy for hepatocellular carcinoma27
The effects of exercise on cancer-related fatigue in breast cancer patients during primary treatment: a meta-analysis and systematic review26
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer26
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy25
Asbestos-related cancers: the ‘Hidden Killer’ remains a global threat25
Current radiotherapy techniques in NSCLC: challenges and potential solutions24
Treatment of recurrent glioblastoma: state-of-the-art and future perspectives23
Optimal treatment in locally advanced cervical cancer22
Pediatric relapsed acute myeloid leukemia: a systematic review21
The role of the microbiome in drug resistance in gastrointestinal cancers21
The emerging role of antibody-drug conjugates in urothelial carcinoma21
What is the best clinical approach to recurrent/refractory osteosarcoma?20
How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer20
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies20
New insights into ErbB3 function and therapeutic targeting in cancer20
Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy18
Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy18
Predicting pathological response to chemoradiotherapy for rectal cancer: a systematic review18
Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis17
Gender discrepancies in bladder cancer: potential explanations17
Is smoking an independent risk factor for developing cervical intra-epithelial neoplasia and cervical cancer? A systematic review and meta-analysis17
Pembrolizumab for advanced cervical cancer: safety and efficacy17
Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy16
A multimodal approach to cancer-related cachexia: from theory to practice16
Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer15
COVID-19: how will this impact children with cancer, now and in the future?15
Radiomics features as predictive and prognostic biomarkers in NSCLC15
Should triple-positive breast cancer be recognized as a distinct subtype?14
Apoferritin: a potential nanocarrier for cancer imaging and drug delivery14
PARP inhibition in treatment of pancreatic cancer14
MRI radiomics in the prediction of therapeutic response to neoadjuvant therapy for locoregionally advanced rectal cancer: a systematic review14
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs14
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors14
Surgical management of intrahepatic cholangiocarcinoma14
Melanoma immunotherapy: strategies to overcome pharmacological resistance13
Osteolytic metastasis in breast cancer: effective prevention strategies13
Cholangiocarcinoma: investigations into pathway-targeted therapies13
Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy13
Palliative care for advanced gastric cancer13
Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer12
Promising predictors of checkpoint inhibitor response in NSCLC12
How can biosimilars change the trajectory of breast cancer therapy?12
microRNAs as biomarkers of ovarian cancer12
Immunosenescence, inflammaging, and cancer immunotherapy efficacy12
The emerging role of PARP inhibitors in prostate cancer12
Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors11
The diagnostic challenges of patients with carcinoma of unknown primary11
Combined endocrine and targeted therapy in luminal breast cancer11
Advances in systemic therapy for the first-line treatment of unresectable HCC11
Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-1911
Neoadjuvant therapy for muscle-invasive bladder cancer11
Clinical management of squamous cell carcinoma of the tongue: patients not eligible for free flaps, a systematic review of the literature11
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma11
Pembrolizumab in the first-line treatment of advanced head and neck cancer11
Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma11
Prostate re-irradiation: current concerns and future perspectives11
Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress11
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions11
The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review11
Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development11
Radiotherapy in the era of COVID-1911
Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis10
Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence10
Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives10
The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments10
Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm10
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma9
The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma9
Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy9
Colorectal cancer screening and diagnosis: omics-based technologies for development of a non-invasive blood-based method9
Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors9
Amivantamab for the treatment ofEGFRexon 20 insertion mutant non-small cell lung cancer9
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance9
Advancements in predicting outcomes in patients with glioma: a surgical perspective9
The potential of cystatin C as a predictive biomarker in breast cancer9
Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature9
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer 9
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem9
Further insights into testicular germ cell tumor oncogenesis: potential therapeutic targets9
The role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies9
Detection ofMETexon 14 skipping mutations in non-small cell lung cancer: overview and community perspective8
Evaluating new treatments for anaplastic thyroid cancer8
A multidisciplinary approach to soft-tissue sarcoma of the extremities8
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma8
Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma8
Current clinical management of elderly patients with glioma8
Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer8
Treatment of cervical cancer: overcoming challenges in access to brachytherapy8
Cemiplimab for locally advanced and metastatic basal cell carcinoma8
Progress in determining response to treatment in gastrointestinal stromal tumor8
Brain metastases in metastatic cancer: a review of recent advances in systemic therapies8
Chemotherapy and targeted treatments of breast sarcoma by histologic subtype8
Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer8
Immune checkpoint inhibition in classical hodgkin lymphoma8
Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis7
Treatment options after first-line immunotherapy in metastatic NSCLC7
High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL)7
Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer7
Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion7
Bladder-sparing treatment options in localized muscle-invasive bladder cancer7
Ribociclib plus fulvestrant in the treatment of breast cancer7
The impact of nutritional status on pancreatic cancer therapy7
Impact of anti-cancer therapy on disease severity and mortality in cancer patients with COVID-19: a systematic review and meta-analysis7
Development of chemotherapeutics for unresectable advanced esophageal cancer7
Evolution in the management of soft tissue sarcoma: classification, surgery and use of radiotherapy7
Immune checkpoint inhibitors for recurrent endometrial cancer7
Measurable residual disease in pediatric acute myeloid leukemia: a systematic review7
Current developments in the combination therapy of relapsed/refractory multiple myeloma7
Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?7
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan7
Factors associated with early lung cancer mortality: a systematic review7
Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician’s guide7
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma7
Therapeutic options in thymomas and thymic carcinomas7
Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma7
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma7
Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives7
miRNA and mRNA expression profiling reveals potential biomarkers for metastatic cutaneous melanoma7
0.03934121131897